Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
|Videos|January 14, 2016
Dr. Alexander Kutikov on Options Afforded to Kidney Cancer Patients
Author(s)Alexander Kutikov, MD, FACS
Kutikov points out that not every mass needs to be resected and that patients need to understand the risks associated with each decision they make in the treatment process.
Advertisement
Alexander Kutikov, MD, FACS, associate professor of Urologic Oncology, Fox Chase Cancer Center, discusses the options patients with a renal tumor have. Kutikov points out that not every mass needs to be resected and that patients need to understand the risks associated with each decision they make in the treatment process.
Advertisement
Related to this article
Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
FDA approves belzutifan plus lenvatinib for advanced clear cell RCC after PD-1/PD-L1 therapy, based on PFS and response rate benefit vs cabozantinib.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Denosumab Biosimilar Approved For Existing Oncology Indications
2
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
3
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
4
Tile-Based Radiation Improves Local Control in Resected Brain Metastases
5